四环医药(00460.HK) 发盈警，预计2024年亏损不超过6亿人民币；及收入不低于18亿人民币。综合因素包括︰集团的仿制药业务受国家集采政策影响持续走低；医美业务延续上半年的走势，保持不低于50%的高速增长；创新药的研发开支仍然保持较高水平；及附属轩竹生物科技授予股权激励产生的一次性费用。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-03 16:25。)
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2024/08/30 | 中期业绩 | 股息：人民币 0.0190 (约相等于 0.021 港元) |
| 2024/03/28 | 末期业绩 | 无派息 |
| 2023/08/29 | 中期业绩 | 无派息 |
| 2023/03/24 | 末期业绩 | 股息：人民币 0.0320 (约相等于 0.037 港元) |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.